振东制药（300158.SZ）9月18日在投资者互动平台表示，公司创新药乳杆菌二联活菌胶囊Pre-NDA申请 已获CDE受理。后续尚需完成提交新药上市申请，经过审评、现场核查等严格的审批审评程序方可上市 销售。公司将根据后续进展情况及时履行信息披露义务，敬请广大投资者谨慎决策，注意防范投资风 险。 每经AI快讯，有投资者在投资者互动平台提问：公司创新药乳杆菌二联活菌胶囊在官网查询已经亮 灯，是否代表本月可以拿到生产批件？ （文章来源：每日经济新闻） ...

Summary of Fosun Pharmaceutical Conference Call Company Overview - **Company**: Fosun Pharmaceutical (复星医药) - **Industry**: Healthcare and Pharmaceuticals Key Points and Arguments 1. **Turnaround Potential**: Fosun Pharmaceutical is expected to reach a turning point with improved profitability across its business segments, particularly in innovative drugs. The company’s product pipeline is considered undervalued, and the ongoing divestiture of non-core assets is anticipated to enhance its financial condition [1][11][12]. 2. **Stock Performance**: Year-to-date, Fosun's A-shares have increased by 29%, while H-shares have risen by 86%. The disparity in performance is attributed to the narrowing of the A-H share premium from 62% at the beginning of 2025 to 34% currently. The significant rise in the stock price of its subsidiary, Henlius, which is up 274% year-to-date, reflects the market's recognition of its innovative drug pipeline [1][11][12]. 3. **Management Changes and Guidance**: The appointment of a new chairman in June 2025 and the announcement of an employee stock ownership plan for A and H shares indicate a strategic shift. The management has set a target for a 20% CAGR in net profit and a 19% CAGR in sales for innovative drugs from 2024 to 2027, suggesting potential upside compared to market expectations [1][11][12]. 4. **Valuation of New Drugs**: By 2030, new drugs are projected to drive 68% of Fosun's valuation, accounting for 45% of total pharmaceutical sales. The innovative drug pipeline, particularly from Henlius, is valued at RMB 72 billion, with significant contributions from key drugs like HLX43, HLX22, and serplulimab [2][20]. 5. **Asset Divestiture Strategy**: High leverage has been a major investment risk. Since 2024, management has reduced debt through the divestiture of non-strategic assets, generating approximately RMB 50 billion in returns. The company aims to achieve annual cash inflows of RMB 30 billion from asset sales over the next three years to improve its capital structure [3][34]. 6. **Upgraded Ratings and Price Targets**: The rating for A and H shares has been upgraded to "Overweight," with target prices set at RMB 42 and HKD 33, respectively. The expected net profit growth rate for 2025 is 20%, driven primarily by the sales ramp-up of new drugs, which is projected to have a CAGR of 18% from 2025 to 2028 [4][38]. 7. **Research and Development Focus**: Fosun's internal R&D team has strategically prioritized its pipeline, focusing on high-value projects while terminating less promising ones. The company has made significant investments in small molecules, cell and gene therapies, and vaccines, with 61-71% of R&D expenditures directed towards its internal pipeline [26][27]. 8. **Clinical Development and Market Potential**: Key drugs in development, such as HLX43 and HLX22, are showing promising clinical data, with HLX43 positioned favorably in the NSCLC market. The company is also exploring additional indications for its drugs, which could further enhance market potential [15][19][18]. 9. **Financial Metrics**: The current market capitalization is approximately RMB 75.215 billion, with an expected EPS of RMB 1.25 for 2025. The company’s PE ratios are projected at 24.0 for 2025, indicating that the stock is undervalued compared to peers [6][12]. Other Important but Overlooked Content - **Subsidiary Performance**: The performance of subsidiaries like Henlius and Gland Pharma is crucial for Fosun's valuation, with Henlius contributing significantly to new drug sales. The management anticipates improvements in profitability from these subsidiaries in the coming quarters [36][37]. - **Market Dynamics**: The healthcare sector in China is experiencing a rebound, with indices like the Hang Seng Healthcare Index showing significant gains. However, Fosun's past performance has been hindered by high debt levels and a mixed business model, which the company is actively working to address [11][12]. - **Future Catalysts**: Upcoming key data readouts and regulatory submissions for its drugs are expected to be significant catalysts for stock performance and market perception [25][36]. This comprehensive summary captures the essential insights from the conference call regarding Fosun Pharmaceutical's current status, strategic direction, and market outlook.

Core Viewpoint - The innovative drug sector in Hong Kong has become a market focus again, with significant stock price increases following a prolonged period of adjustment and low valuations [2][3]. Group 1: Market Performance - Beihai Kangcheng-B (01228.HK) has surged nearly 19 times, while other companies like Deqi Pharmaceutical-B (06996.HK) and Hengrui Medicine (01276.HK) have also shown impressive gains, with some stocks increasing over four times [2]. - The overall profitability of the Hong Kong innovative drug sector has significantly improved in 2025, with many companies reporting substantial increases in net profit [6][7]. Group 2: Policy Support - The Chinese government has included "innovative drugs" in key emerging industries, with policies introduced to support the development of innovative drugs, including price management and financing [3]. - In June 2025, the National Healthcare Security Administration and the National Health Commission launched measures to support the high-quality development of innovative drugs, providing robust policy backing [3]. Group 3: Company Performance - Hengrui Medicine reported a 29.67% increase in net profit to 4.45 billion RMB in the first half of the year, achieving record highs in revenue and profit [4]. - Baijie Shenzhou's net profit increased by 115.63% to 450 million RMB, marking its first half-year profit, primarily due to the strong performance of its core product [5]. Group 4: Financing Trends - Many innovative drug companies are launching placement financing plans to raise funds for ongoing research and daily operations, driven by improved stock prices [8][10]. - As of 2025, nearly 60 companies in the Hong Kong medical and biopharmaceutical sectors have announced placement financing plans, with innovative drug companies being the main contributors [8]. Group 5: Future Outlook - The innovative drug sector is expected to continue its rapid development, supported by favorable external conditions and ongoing policy support [12][14]. - The recent interest rate cuts by the Federal Reserve may facilitate easier financing for innovative drug companies, which is crucial for those yet to achieve commercialization [13].

Market Overview - The Hong Kong stock market experienced a significant decline in the afternoon, with major indices dropping over 2% after reaching recent highs earlier in the day. The Hang Seng Index closed down 1.35%, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.46% and 0.99%, respectively [1][2]. Sector Performance - The technology sector, which had previously driven market gains, saw a broad pullback, with major financial stocks (banks, insurance, and brokerage firms) collectively dragging the market down. Real estate stocks faced substantial declines, reflecting ongoing market adjustments, with coal, home appliance, education, catering, gaming, and gold stocks also experiencing losses [2][3]. - Semiconductor stocks maintained strong performance amid news of anti-dumping investigations and rumors of a ban on Nvidia, with Huahong Semiconductor rising by 8.6% and leading firm SMIC reaching a historical high [2][10]. Notable Stock Movements - Major technology stocks such as Xpeng Motors, Haier Smart Home, and Bilibili saw declines exceeding 3%, while Tencent, Alibaba Health, and Midea Group also fell [4][5]. - Real estate stocks collectively dropped, with Country Garden falling over 10% and other firms like Jin Hui Holdings and Oceanwide Holdings declining by more than 7% [6]. - Chinese brokerage stocks also fell, with Hongye Futures down over 5% and other firms like Zhongzhou Securities and CITIC Securities following suit [7][8]. - Education stocks faced significant declines, with China Education Industry dropping over 9% and other firms like Zhongjiao Holdings and Huazhong Education also experiencing losses [9]. - The semiconductor and chip sectors saw gains, with ASMPT and Huahong Semiconductor both rising over 8% [10]. - The innovative drug sector performed well, with companies like Crystal Technology and Heng Rui Pharmaceutical seeing increases of over 5% [11]. Capital Flows - Southbound capital recorded a net inflow of HKD 6.288 billion, with net purchases of HKD 1.907 billion through the Shanghai-Hong Kong Stock Connect and HKD 4.382 billion through the Shenzhen-Hong Kong Stock Connect [13]. Future Outlook - Analysts predict a "super long bull market" for Hong Kong stocks, with expectations that the Hang Seng Index could reach around 28,000 points by November, and the Hang Seng Tech Index may target a range of 6,000 to 6,200 points [15].

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and other services (0.59%) [7]. Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2]. - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the U.S., EU, and Australia [2]. - Junshi is advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - The company is collaborating with various research institutions to develop vaccines, including monkeypox and Zika vaccines, which are currently in preclinical development [3]. - A partnership with Peking University and other institutions has been established to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the first half of 2025, Junshi Biosciences reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, reflecting a 36.01% increase [8]. - As of June 30, 2025, the number of shareholders increased by 5.88% to 31,200, with a decrease in average circulating shares per person by 5.56% [8]. Market Activity - On September 18, the stock price of Junshi Biosciences increased by 0.20%, with a trading volume of 909 million yuan and a turnover rate of 2.57%, resulting in a total market capitalization of 46.951 billion yuan [1]. - Recent trading activity indicates a net outflow of 31.6178 million yuan from main funds, with a lack of clear trends in main fund movements [4][5].

Core Viewpoint - The innovation drug ETFs are experiencing significant capital inflow and market interest, with specific companies showing strong performance and new product approvals enhancing market sentiment [1][2][3] Group 1: ETF Performance - The Tianhong Innovation Drug ETF (517380) saw a slight decline of 0.46% but has been experiencing notable premium trading, with a net capital inflow exceeding 180 million yuan over the past eight trading days [1] - The Biopharmaceutical ETF (159859) rebounded to a 0.22% increase after an initial drop, with a trading volume exceeding 160 million yuan, indicating strong market activity [1] Group 2: Company Developments - Heng Rui Medicine announced that its subsidiary received a notice from the National Medical Products Administration regarding the acceptance of a new indication for its drug SHR-A1811, which is now under priority review [2] - The drug has already been approved for treating specific types of lung cancer, showcasing the company's ongoing innovation and regulatory progress [2] Group 3: Market Sentiment and Trends - Recent reports indicate that while there are concerns about the overseas expansion of innovation drugs, Chinese companies possess competitive advantages in high-efficiency and low-cost development [3] - Major overseas pharmaceutical companies are facing challenges and are increasingly looking to Chinese innovation for resource acquisition, which could enhance the competitive landscape for Chinese firms [3] - Analysts remain optimistic about the long-term growth potential of the innovation drug sector, particularly in the Hong Kong market, while also highlighting the value of core assets in the A-share market [3]

Company Overview - Baihua Medicine has seen a stock price increase of 52.05% year-to-date, with a recent 0.10% rise over the last five trading days, 16.24% over the last 20 days, and 40.93% over the last 60 days [2] - The company has appeared on the stock market's "Dragon and Tiger List" four times this year, with the most recent appearance on September 4, where it recorded a net buy of -57.5752 million yuan [2] - Baihua Medicine's main business includes early drug discovery, drug CMC development, clinical trials, registration applications, and various pharmaceutical services [2] Financial Performance - As of June 30, the number of shareholders for Baihua Medicine was 30,000, a decrease of 26.42% from the previous period, while the average circulating shares per person increased by 35.95% to 12,799 shares [3] - For the first half of 2025, Baihua Medicine reported revenue of 202 million yuan, a year-on-year increase of 2.95%, and a net profit attributable to shareholders of 25.4834 million yuan, up 12.45% year-on-year [3] Revenue Composition - The revenue composition of Baihua Medicine is as follows: clinical trials account for 49.39%, pharmaceutical research and consistency evaluation for 42.67%, leasing and property services for 6.69%, and other income for 0.94% [2] Market Activity - On September 18, Baihua Medicine's stock price fell by 2.05% to 10.02 yuan per share, with a trading volume of 278 million yuan and a turnover rate of 7.07% [1] - The net inflow of main funds was 4.0879 million yuan, with large orders accounting for 19.69% of purchases and 18.16% of sales [1]

该行认为，公司中间体原料药具有龙头地位、竞争格局稳定，短期受需求减弱而承压；又认为行业竞争 格局稳固，联邦为青霉素绝对龙头，随着需求趋稳，有望企稳回升。该行预计公司2025至2027年分别实 现收入133.5亿、127.7亿、139.3亿元，实现归母净利润分别为25.9亿、23.4亿、25.2亿元。 招商证券发表研究报告指，首予联邦制药"强烈推荐"评级，认为公司主业抗生素有望逐步企稳，胰岛 素、动保持续开拓增长新曲线，创新加速发展，成长空间广阔。创新药方面，公司三靶点GLP-1激动剂 UBT251海外权益成功授权诺和诺德，有望持续贡献催化，后续减重管线中长效PYY类似物、口服GLP- 1小分子早期数据优异，有出海潜力，建议关注。 ...

Core Viewpoint - Shuyou Shen's stock price has shown significant volatility, with a year-to-date increase of 409.18%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1]. - The main revenue sources are: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1]. Financial Performance - For the first half of 2025, Shuyou Shen reported revenue of 126 million yuan, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.64 million yuan, a decline of 619.70% [2]. - The company has distributed a total of 771 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, with an average of 14,327 shares held per shareholder, a decrease of 22.60% [2]. - New institutional shareholders include several funds, with notable holdings such as 15.72 million shares by Xingquan Helun Mixed A and 8.81 million shares by Xingquan Commercial Model Mixed A [3]. Market Activity - On September 18, the stock price rose by 2.00% to 37.73 yuan per share, with a trading volume of 521 million yuan and a turnover rate of 3.09%. The total market capitalization reached 18.026 billion yuan [1]. - The stock has appeared on the daily trading leaderboard seven times this year, with the most recent occurrence on June 9, where it recorded a net buy of -54.65 million yuan [1].

恒瑞医药子公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗（SHR-A1811）的药品上市许可申请获受理，且已被纳入优先审评程序，本品适用于治疗既往接受过一种或 天风证券指出，恒瑞医药实现上半年归母净利润44.50亿元，同比增长29.67%；2025二季度归母净利润为25.76亿元，同比增长24.88%。2025上半年创新药进入快速放量阶段，国际化贡献利 责任编辑：卢昱君 恒瑞医药（01276）午前拉升逾7%，高见91港元，再创上市新高。截至发稿，股价上涨5.42%，现报89.50港元，成交额3.22亿港元。 ...